Bionity Corporate Overview


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Bionity Corporate Overview

  1. 1. Corporate Overview
  2. 2. Corporate Overview   BIONITY is an independent consulting firm focusing on complex project assessment, valuation, financial advisory, IPR consultancy, market analysis and licensing. Budapest   We provide our services mainly to biotech, pharma, medtech companies, life sciences focused investors and academic research institutions.   Our office is located in Budapest, Hungary, with a broad activity in Central Eastern Europe.|
  3. 3. Our Industry Focus:Life Sciences 1.   PreClinical / Clinical Stage Drug Development Projects   Platform & Drug Delivery Technologies 2.   Medical Device Developments   Diagnostics & Analytical Technologies 3.   CROs & SMOs   BioInformatics 4.   Development of API & Biological Manufacturing Capacities|
  4. 4. |
  5. 5. Pipeline Review and Valuations Our expertise in financial valuation combined with our strategic partners - specialized in legal, regulatory affairs & IPR - opens the door to a comprehensive and sound review of pipelines.   Scenario Analysis   Value of each project scenario   Value of pipeline   Risk profile of pipeline   Sales forecasts of each project (worst case, base case, best case)   Defining key inflection points and value creation of projects.|
  6. 6. Market Analysis We support our clients with deep market assessment, and competitive analysis to get a sound insight into . Market analysis can be combined with competitor and product surveillance.   SWOT and Five Forces Analysis   Desk researches about competitive landscape and market potentials   Primary Reseaches, Interviewing Key Opinion Leaders (KOLs)   Analysis of the Probabilities of Success   Analysis of potential market acceptance, Willingness to Prescribe   Evaluation of Peak Sales dynamics, volatility, elasticity|
  7. 7. FDI Promotion Central and Eastern Europena life sciences sector is characterized with highly skilled workforce, stable political and regulatory system & strong governmental commitment. Whether it is a specialized R&D unit or a large greenfield manufacturing plant, we help our clients to find the rigth local partnes and ideal location.   Market intelligence   Feasibility studies on Foreign Direct Unvestments   Academic, corporate match-making (R&D partners, subcontractors)   Site Evaluation and Pre-selection services   Negotiation with investment promotion agencies   Supporting foreign companies to obtain permissions on fast-track|
  8. 8. Strategic Financing Our strong network with Life Sciences focused VCs , CVCs and HNWIs is prerequested to reach and meet suitable investor(s) corresponding to the financial needs, pipeline and stage of development.   Reviewing the Teaser and Company Presentation   Elaboration of Mid-term individual financial Strategies   Defining and continously updateing the „Investors List   Planning and organizing one-on-one meetings with potential investors   Structuring the Term Sheet and assisting on the Due Diligence process   Corporate restructuring and Corporate governance related to deals|
  9. 9. Raising Capital The discount rate for the valuation is elaborated for each company individually based on our sound model that takes into account the development stage of the pipeline projects, IP positions, indications, stand-alone and market risks, operating costs and the business strategy of the Company.   CashFlow Analysis   Profit and Loss Statement (P&L)   Risk-Adjusted Net Present Value Calculations (rNPV)   Real-Options Valutions (ROV)   Deal-Sourcing and Pre-Selection Services for professional Investors|
  10. 10. Licensing and Partnering For a BioPharma company, securing IPR and exploiting such rights by licensing/partnering constitute some of the most fundamental aspects of the business. We help define which rights should be licensed and what type of license should be granted.   Developing Licensing Strategy   License contract value for licensee and licensor (rNPV, Real Options)   IRR for licensee and licensor   Value share between licensor and licensee   Identifying and contacting potential licensing partners   Implementing, negotiating and managing License-In & Out deals   Advising on Term Sheets and Licensing Agreements|
  11. 11. Professional Background Before founding Bionity R&D Investment Advisors in 2007, he was the director of the CEE activities at PCA Capital Advisors (2005-2007), a Frankfurt based corporate finance boutique focusing on biotechnology and ICT financing. Before he held the position of “Head of Priority Sectors” at the Hungarian Investment and Trade Development Agency, ITDH (2002-2005). He is fluent in English and French. He is the Board Member of the Hungarian Biotechnology Association and member of the SME Platform of EuropaBio.   Marcell Veidner He graduated in March 2011 at Biotech focused MBA program of IE Business School (Madrid, Managing director Spain), a globally top ranked business school. He has been graduating at Budapest University of Economic Science and Administration with major in entrepreneurship, and also obtained +3620.284.9662 Master degree in “European Studies” at the same institution.|
  12. 12. Partnerships and Membership Cogito Consuiting is an IPR and technology valuation specialist consulting firm located in Budapest. Its expertise include novelty, patentability, FTO analysis and strategic IPR consulting. Cogito is also supporting its clients with evaluation of the market potential of new technologies. The Hungarian Biotechnology Association (HBA) was established by Hungarys leading human biotechnology companies with the aim of promoting the development and representation of the Hungarian biotechnology sector.|
  13. 13. + H-1036, Budapest Perc u. 6.